IRSI Genotype Modulates Metabolic Syndrome Reversion in Response to 2-Year Weight-Loss Diet Intervention

QIBIN QI, PhD1
MIN XI, MD, PhD1
HONGYU WU, PhD1
LIMING LIANG, PhD2
CATHERINE M. CHAMPAGNE, PhD3
GEORGE A. BRAY, MD3
FRANK M. SACKS, MD1
LU QI, MD, PhD1,4

OBJECTIVE—Genetic variants near IRS1 are associated with features of the metabolic syndrome (MetS). We examined whether genetic variants near IRS1 might modulate the effects of diets varying in fat content on the MetS status in a 2-year weight-loss trial.

RESEARCH DESIGN AND METHODS—Two variants near IRS1, rs1522813 and rs2943641, were genotyped in 738 overweight/obese adults (age 60 ± 9 years; BMI 32.7 ± 3.9 kg/m²) randomly assigned to one of four weight-loss diets (a deficit of 750 kcal/day of caloric intake from baseline) varying in macronutrient contents for 2 years. We compared MetS status of high-fat (40% of caloric intake; n = 370) and low-fat (20% caloric intake; n = 368) diet groups differentiated by genotypes (rs1522813 A-allele carriers and noncarriers; rs2943641T-allele carriers and noncarriers).

RESULTS—Among rs1522813 A-allele carriers, the reversion rates of the MetS were higher in high-fat diet group than those in low-fat diet group over the 2-year intervention (P = 0.002), while no significant difference between diet groups was observed among noncarriers (P = 0.27). The genetic modulation on dietary effect was independent of weight changes. The odds ratio (OR) for the 2-year reversion of the MetS was 2.88 (95% CI 1.25–6.77) comparing the high-fat and low-fat diets among rs1522813 A-allele carriers, while the corresponding OR was 0.83 (0.36–1.92) in noncarriers. The variant rs2943641 was not observed to modulate dietary effects on the MetS status.

CONCLUSIONS—Our data suggest that high-fat weight-loss diets might be more effective in the management of the MetS compared with low-fat diets among individuals with A-allele of the rs1522813 variant near IRS1.

The metabolic syndrome (MetS) is a constellation of metabolic abnormalities including abdominal obesity, dyslipidemia (low HDL-cholesterol levels, and hypertriglyceridemia), elevated blood pressure, and hyperglycemia (1). It has been well-documented that dietary intervention is an effective way to manage the MetS (2–9), though a specific therapeutic diet for the MetS remains to be determined. We have previously shown that weight-loss diets varying in macronutrient components had similar effectiveness in reducing the prevalence of the MetS in a 2-year randomized clinical trial, the Preventing Overweight Using Novel Dietary Strategies (POUNDS LOST) trial (10).

Genetic factors may play an important role in the development of the MetS. Insulin receptor substrate 1 (IRS1), encoded by the IRS1 gene, plays a key role in the insulin signaling pathway (11–13). Recent genome-wide association studies have identified common genetic variants near the IRS1 gene associated with multiple features of the MetS, such as insulin resistance, abdominal obesity, and dyslipidemia, as well as risk of diabetes and coronary heart disease (14–17). Moreover, our previous gene–diet interaction analysis has shown that the genetic variant rs2943641 near IRS1 might modulate the effect of diets varying in fat content on weight loss and the improvement of insulin resistance (18). Thus, we hypothesized that genetic variation near IRS1 may also modify the effect of weight-loss diets varying in fat content on the MetS status.

In the current study, we genotyped another genetic variant, rs1522813, for which occurrence is independent of the previously investigated genetic variant rs2943641 (r² < 0.01) and is also near IRS1, and compared the effects of the high-fat and low-fat diets on the reversion of the MetS according to genotypes of the two variants over a 2-year intervention in 738 overweight or obese adults from the POUNDS LOST trial.

RESEARCH DESIGN AND METHODS

Study participants
The POUNDS LOST trial is a 2-year randomized clinical trial to compare the effects of energy-reduced diets with different compositions of fat, protein, and carbohydrate on weight change. The study design and methods have been described in detail elsewhere (10). A total of 811 overweight or obese subjects were randomly assigned to one of four diets for...
participants had to be 30–70 years of age and have a BMI of 25–40 kg/m². The target percentages of energy derived from fat, protein, and carbohydrate in the four diets were 20, 15, and 65%; 20, 25, and 55%; 40, 15, and 45%; 40, 25, and 35%, respectively. Each participant’s caloric prescription represented a deficit of 750 kcal/day from baseline, as calculated from the person’s resting energy expenditure and activity level. By constituting a two-by-two factorial design, two diets were low-fat (20%) and two were high-fat (40%), and two were average-protein (15%) and two were high-protein (25%). Major criteria for exclusion were the presence of diabetes or unstable cardiovascular disease, the use of medications that affect body weight, and insufficient motivation. In the current analysis, 738 subjects with genotype data were included (91% of the total subjects in the POUNDS LOST trial). Among them, 61% were women, 80% were white, 15% were African American, 3% were Hispanic, and 2% were Asian or other ethnic groups by self-report. The study was approved by the human subjects committee at the Harvard School of Public Health and Brigham and Women’s Hospital, Boston, MA, and the Pennington Biomedical Research Center of the Louisiana State University System, Baton Rouge, LA, and by a data and safety monitoring board appointed by the National Heart, Lung, and Blood Institute. All participants gave written informed consent.

Measurements
Body weight and waist circumference were measured in the morning before breakfast at baseline, 6 months, and 2 years. Height was measured at baseline. BMI was calculated as weight (kg)/height² (m²). Fasting blood samples were collected at baseline, 6 months, and 2 years, and serum glucose, insulin, HDL cholesterol, and triglycerides were measured at the clinical laboratory at the Pennington Biomedical Research Center. Insulin resistance was estimated by homeostasis model assessment of insulin resistance calculated by the following equation: (fasting insulin [µU/mL] × fasting glucose [mg/dL]/18.01)/22.5 (19). Blood pressure was measured at baseline, 6 months, and 2 years with the use of an automated device (HEM-907XL; Omron). To assess the dietary adherence across the intervention, dietary intake was assessed in a random sample of 50% of the participants by a review of the 5-day diet record at baseline and by 24-h recall during a telephone interview on 3 nonconsecutive days at 6 months and 2 years. In addition, food frequency questionnaires were collected in all participants at baseline, 6 months, and 2 years. Participants’ physical activity levels were assessed using the Baecke physical activity questionnaire (20) at baseline, 6 months, and 2 years.

Genotyping
DNA was extracted from the buffy coat fraction of centrifuged blood using the QIAPrep Blood Kit (Qiagen, Chatsworth, CA). Single nucleotide polymorphisms (SNPs) were genotyped using the OpenArray SNP Genotyping System (BioTrove, Woburn, MA). Replicate quality control samples (10%) were included and genotyped with >99% concordance. In addition to the previously reported SNP rs2943641 (18), we genotyped another SNP rs1522813, which showed stronger association with type 2 diabetes than the SNP rs2943641 in our previous analysis (21). The allele frequencies of both SNPs in all participants or in white participants were in Hardy-Weinberg equilibrium ($P > 0.05$).

Definition of the MetS
The MetS was defined based on the National Cholesterol Education Program Adult Treatment Panel III criteria as presenting at least three of the following components: 1) abdominal obesity: waist circumferences ≥102 cm in men or ≥88 cm in women; 2) hyperglyceridemia: triglycerides ≥1.71 mmol/L (150 mg/dL); 3) low HDL-cholesterol levels: HDL cholesterol <1.03 mmol/L (40 mg/dL) in men or <1.29 mmol/L (50 mg/dL) in women; 4) high blood pressure: blood pressure ≥130/85 mm Hg or current use of antihypertensive medications; or 5) hyperglycemia: fasting plasma glucose ≥6.1 mmol/L (110 mg/dL) (1). Participants who met the criteria for MetS at baseline but not at the 6-month or 2-year assessment were defined as the MetS reversion, while participants who did not meet criteria for MetS at baseline but met the criteria at the 6-month or 2-year assessment were defined as the MetS incidence.

Statistical analysis
General linear models for continuous variables and $χ²$ test for categorical variables were applied for the comparison according to genotype groups at baseline. We compared the prevalence of the MetS and changes in the MetS status (reversion rate and incidence rate) between low-fat and high-fat diet groups by genotype groups at 6 months and 2 years using the $χ²$ test. We used logistic regression models to calculate the odds ratios (ORs; [95% CI]) of the reversions of the MetS and individual components by comparing the high-fat diets with the low-fat diets stratified by genotype groups, adjusted for age, sex, ethnicity, and changes in body weight. Gene–diet intervention interactions were tested by including the genotype-by-diet interaction terms in the models. We also used mixed models to test the dietary effects on the reversion of the MetS according to genotype groups over the 2-year intervention. Considering the relatively small numbers of minor homozygotes, heterozygote and minor homozygotes were combined in the analyses. Because the majority of the participants were white (80%), similar analyses were repeated in white participants. All reported $P$ values are nominal and two-sided, and a $P$ value of 0.05 was considered statistically significant. Statistical analyses were performed with SAS version 9.1 (SAS Institute, Inc., Cary, NC).

RESULTS—Table 1 shows the baseline characteristics of participants according to the SNP rs1522813 genotype. The genotype frequencies were similar between men and women, among ethnic groups, and across the diet groups (all $P > 0.16$). The prevalence of elevated blood pressure decreased across the genotype groups ($P = 0.02$), but there was no significant difference in the prevalence of the MetS or other individual components of the MetS among the rs1522813 genotype groups (all $P > 0.12$). The other SNP, rs2943641, showed weak linkage disequilibrium with the SNP rs1522813 ($r^2 = 0.004$, 0.007, and 0.007; $D' = 0.122$, 0.244, and 0.475, respectively, in the HapMap Centre d’Etude du Polymorphisme Humain from Utah [CEU], Yoruba from Ibadan [YRI], and Japanese population from Tokyo [JPT] + Han Chinese from Beijing [CHB] database [http://hapmap.ncbi.nlm.nih.gov/], respectively). The baseline characteristics of participants according to the SNP rs2943641 genotype have been previously reported (18). No significant differences in the prevalence of the MetS or individual components across the genotype groups were observed (data not shown).

After dietary intervention, the overall prevalence of the MetS was reduced from...
Logistic regression analysis confirmed that high-fat diets were associated with the reversion of the MetS among participants with the rs1522813 A-allele (GA/AA genotypes) (Fig. 1). After adjusted for age, sex, ethnicity, and body weight changes, the ORs (95% CI) for the 6-month MetS reversion for the high-fat diet group compared with low-fat diet group were 2.31 (1.12–4.68) among participants with GG genotype over the 2-year intervention.

Table 2 shows the effect of low-fat and high-fat diets on changes in the MetS status in response to diet among participants with the rs1522813 A-allele (GA/AA genotypes) (Fig. 1). Among participants with GA/AA genotype, the MetS reversion rate was higher in the high-fat diet group than in the low-fat diet group (P = 0.002), while the low-fat and high-fat diets showed similar effects on reversion of the MetS (P = 0.27) among participants with GG genotype over the 2-year intervention.

We finally examined the dietary effects on reversion of the components of the MetS by the SNPrs1522813 genotype. Among participants with the rs1522813 GA/AA genotype, the high-fat diets showed directionally consistent effects on reversions of the MetS components compared with the low-fat diets, but the results did not reach a statistically significant level (all P > 0.05) (Supplementary Table 1). We observed marginal diet–genotype interactions on the reversion of high blood pressure at 6 months (P for interaction = 0.07) and the reversion of hypertriglyceridemia at 2 years (P for interaction = 0.08).

**Conclusions**—In this 2-year weight-loss trial, we examined the effects of variants near the IRS1 gene on changes in the MetS status in response to...
weight-loss diets with two different prescribed levels of fat content. We found a potential interaction between the genetic variant rs1522813 and diet intervention on reversion of the MetS at 6 months and 2 years. Among individuals with the rs1522813 A-allele, the high-fat diets showed greater effect on reversion of the MetS compared with the low-fat diets over the 2-year intervention.

Although a large body evidence has shown that dietary interventions are beneficial in the management of the MetS, the ideal dietary intervention remains controversial (3–9). In our previous analysis of the POUNDS LOST trial, weight-loss diets with different macronutrient components had similar effectiveness in improving the MetS (10). Our recent gene–diet interaction analyses in the POUNDS LOST trial have suggested that the effects of the diet intervention on body weight and related metabolic traits might be influenced by genetic background (18,22–26). In the current study, our data indicated that high-fat diets were superior to the low-fat diets on reversion of the MetS among individuals with A-allele of the rs1522813 variant near IRS1. The observed genotype–diet interaction on reversion of the MetS might be independent of weight loss or changes in insulin resistance. This is consistent with the results that we did not find significant genotype–diet interaction on weight loss or changes in insulin resistance. Moreover, the results were similar when we excluded the criterion for waist circumference in the definition of the MetS, further suggesting the genotype–diet interaction on reversion of the MetS might be less influenced by changes in adiposity. Unlike the weight regain after 6 months, the dietary effect in reducing the prevalence of the MetS persisted at 2 years in the POUNDS LOST trial (10). This may also explain the consistent results at 6 months and 2 years regardless of weight changes during the intervention. Therefore, these results indicate a stable and long-term dietary effect in reducing the prevalence of the MetS, but the high-fat diet showed directional consistent improvement on reversion of the MetS components compared with the low-fat diets among participants with the rs1522813 A-allele. These results suggested that the dietary effect on reversion of the MetS might reflect the cumulative effects on the individual components rather than on any single component. This is in line with the fact that genetic variants near IRS1 were associated with multiple features of the MetS (14–17,21), though the fact of these genetic variants has not been clarified. Individuals with the rs1522813 A-allele, which is the risk allele for type 2 diabetes, had a higher reversion rate of the MetS by choosing a high-fat diet compared with those without the A-allele. This is consistent with some previous results that the risk alleles of the genetic variants were

Table 2—Metabolic syndrome status and weight loss between diet groups by rs1522813 genotype at baseline, 6 months, and 2 years

<table>
<thead>
<tr>
<th>Baseline</th>
<th>Low-fat diets</th>
<th>High-fat diets</th>
<th>P value*</th>
<th>Low-fat diets</th>
<th>High-fat diets</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants (n)</td>
<td>187</td>
<td>199</td>
<td>0.13</td>
<td>181</td>
<td>171</td>
<td>0.31</td>
</tr>
<tr>
<td>Prevalence [n (%)]</td>
<td>97 (51.9)</td>
<td>88 (44.2)</td>
<td>0.65</td>
<td>76 (42.0)</td>
<td>81 (47.4)</td>
<td>0.31</td>
</tr>
<tr>
<td>6 months</td>
<td>Participants (n)</td>
<td>171</td>
<td>177</td>
<td>158</td>
<td>153</td>
<td></td>
</tr>
<tr>
<td>Prevalence [n (%)]</td>
<td>60 (35.1)</td>
<td>58 (32.8)</td>
<td>0.65</td>
<td>57 (36.1)</td>
<td>48 (31.4)</td>
<td>0.38</td>
</tr>
<tr>
<td>Reversion [n (%)]†‡</td>
<td>34 (37.8)</td>
<td>24 (31.2)</td>
<td>0.37</td>
<td>20 (27.8)</td>
<td>32 (42.7)</td>
<td>0.06</td>
</tr>
<tr>
<td>Incidence [n (%)]‡</td>
<td>4 (4.9)</td>
<td>5 (5.0)</td>
<td>0.98</td>
<td>5 (5.8)</td>
<td>5 (6.4)</td>
<td>0.87</td>
</tr>
<tr>
<td>Weight loss (kg)</td>
<td>-6.7 ± 0.4</td>
<td>-6.6 ± 0.4</td>
<td>0.83</td>
<td>-6.9 ± 0.5</td>
<td>-6.3 ± 0.5</td>
<td>0.33</td>
</tr>
<tr>
<td>Weight loss percentage</td>
<td>-7.3 ± 0.4</td>
<td>-7.3 ± 0.4</td>
<td>0.97</td>
<td>-7.3 ± 0.5</td>
<td>-6.7 ± 0.5</td>
<td>0.42</td>
</tr>
<tr>
<td>2 years</td>
<td>Participants (n)</td>
<td>142</td>
<td>150</td>
<td>144</td>
<td>124</td>
<td></td>
</tr>
<tr>
<td>Prevalence [n (%)]</td>
<td>46 (32.4)</td>
<td>48 (32.0)</td>
<td>0.94</td>
<td>50 (34.7)</td>
<td>41 (33.1)</td>
<td>0.78</td>
</tr>
<tr>
<td>Reversion [n (%)]†‡</td>
<td>29 (40.9)</td>
<td>23 (34.9)</td>
<td>0.47</td>
<td>18 (28.1)</td>
<td>28 (45.9)</td>
<td>0.04</td>
</tr>
<tr>
<td>Incidence [n (%)]‡</td>
<td>5 (4.5)</td>
<td>6 (5.0)</td>
<td>0.93</td>
<td>4 (5.0)</td>
<td>8 (12.7)</td>
<td>0.10</td>
</tr>
<tr>
<td>Weight loss (kg)</td>
<td>-4.3 ± 0.6</td>
<td>-4.1 ± 0.6</td>
<td>0.77</td>
<td>-4.0 ± 0.6</td>
<td>-3.7 ± 0.6</td>
<td>0.70</td>
</tr>
<tr>
<td>Weight loss percentage</td>
<td>-4.6 ± 0.6</td>
<td>-4.6 ± 0.6</td>
<td>0.98</td>
<td>-4.1 ± 0.6</td>
<td>-3.9 ± 0.6</td>
<td>0.87</td>
</tr>
</tbody>
</table>

*P values were calculated by χ² test for categorical variables and general linear models for continuous variables. †Participants who met the criteria for MetS at baseline but not at the 6-month or 2-year assessment. ‡Participants who did not meet criteria for MetS at baseline but met the criteria at the 6-month or 2-year assessment.
associated with greater beneficial effects of diet interventions (18, 27). The potential mechanisms underlying these findings remain to be investigated. In addition, it is difficult to distinguish the effects of dietary fat and carbohydrate responsible for the observed interactions, because the high-fat diets have low carbohydrate content.

To the best of our knowledge, this is the first study to date to investigate the gene–diet interactions on changes in the MetS status in a large and long-term randomized trial. However, several limitations of our study need consideration. Not all participants included in the analysis had MetS at baseline (~50% of the participants met the criteria for the MetS). This may also limit our statistical power of the analysis for the reversion of the MetS, and our study may be underpowered to detect modest effects and interactions. As expected, our findings barely reached the level of statistical significance, and replication of these results is needed in future. Participants had difficulty achieving the goals for macronutrient intake of their assigned group, but mean differences in fat, carbohydrate, or protein intake among the diet groups were significant (10). Because of the relatively small numbers of incident cases of the MetS, we did not analyze the incidence of the MetS, and it is unknown whether the gene–diet interactions were similar to the prevention of the MetS. The participants of our study were overweight or obese; therefore, further studies are warranted to investigate whether our findings are applicable in people with normal weight. In addition, most of the participants were whites (~80%), and it remains to be determined whether our findings could be generalized to other ethnic groups.

In conclusion, we found that the genetic variant rs1522813 near IRS1 might modulate the effects of weight-loss diets with different fat content on the MetS status in a 2-year randomized trial. Participants with the rs1522813 A-allele might have a higher reversion rate of the MetS by choosing a high-fat diet compared with a low-fat diet. These novel findings provide supportive evidence for the notion of a personalized dietary intervention in the management of the MetS.

Acknowledgments—This study was supported by grants from the National Heart, Lung, and Blood Institute (HL-071981), the National Institute of Diabetes and Digestive and Kidney Diseases (DK-091718), the National Cancer Institute (CA-155626), the General Clinical Research Center (RR-02635), and the Boston Obesity Nutrition Research Center (DK-46200). L.Q. is a recipient of the American Heart Association Scientist Development Award (0730094N).

No potential conflicts of interest relevant to this article were reported.

Q.Q. designed the study, researched data, and wrote the manuscript. M.X., H.W., L.L., and C.M.C. researched data, contributed to discussion, edited, and reviewed the manuscript. G.A.B. and F.M.S. contributed to discussion and edited and reviewed the manuscript. L.Q. designed the study, reviewed data, contributed to discussion, and edited and reviewed the manuscript. L.Q. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

This study was presented in abstract form at the 72nd Scientific Sessions of the American Diabetes Association, Philadelphia, Pennsylvania, 8–12 June 2012.

The authors thank the participants in the trial for their dedication and contribution to the research.

References


